Business
Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips
NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral
About this update from Immunic, Inc.
[{"type":"text","content":"NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Barclay \"Buck\" A. Phillips, an established life sciences executive, investor and entrepreneur, to its Board of Directors, effective November 14, 2019. With this addition, Immunic's Board will total seven members.\n\"Buck's decades of relevant experience in the biotechnology sector, both as a Chief Financial Officer and investor, will add a unique perspective to our Board,\" stated Duane Nash, M.D., J.D., M.B.A., Chairman of the Board of Directors of Immunic. \"We look forward to leveraging his significant expertise in the areas of financing strategy, capital markets, business development, and others, which he has garnered during his successful career as an executive and board member for multiple, Nasdaq-listed life science companies. Buck's addition to our team reflects our desire to build the Board during a time of continued clinical progress and we look forward to his contributions.\"\nUntil recently, Mr. Phillips was Chief Financial Officer and Senior Vice President of Corporate Development at G1 Therapeutics, Inc., where, among other achievements, he was instrumental in raising over USD 300 million in multiple equity financings. Before that, he served as Senior Vice President, Chief Financial Officer and Treasurer of vaccine company, Novavax, Inc., where he helped to raise more than USD 850 million in various financings to support the company's late-stage clinical programs. Prior, Mr. Phillips was Senior Vice President and Chief Financial Officer of Micromet, Inc., which, during his tenure, was acquired by Amgen Inc. for approximately USD 1.2 billion. Mr. Phillips's exposure to venture capital came earlier, while serving as a Managing Director at Vector Fund Management, focused on investments in late-stage life sciences companies, and during his time as Biotechnology Analyst and Director of Venture Investments at Invesco, where he held primary coverage responsibility for the universe of publicly traded biotechnology companies, while managing the firm's private equity investing, with a focus on life sciences.\nMr. Phillips has served on the boards of over a doze...